Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal

Free Radical Biology and Medicine

Volumn 111, Issue , 2017, Pages 281-293

  Romano, Adele ^a   Serviddio, Gaetano ^b   Calcagnini, Silvio ^a   Villani, Rosanna ^b   Giudetti, Anna Maria ^c   Cassano, Tommaso ^b   Gaetani, Silvana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF SALENTO   (Italy)

Author keywords

4 hydroxy 2 nonenal; bipolar disorders; depression; Huntington's disease; neuropsychiatric disorders; Parkinson's disease; schizophrenia

Indexed keywords

4 HYDROXYNONENAL; FREE RADICAL; METAL ION; 4-HYDROXY-2-NONENAL; ALDEHYDE; IRON; NEUROPROTECTIVE AGENT;

BIPOLAR DISORDER; BLOOD LEVEL; BRAIN LEVEL; BRAIN REGION; HUMAN; HUNTINGTON CHOREA; LIPID PEROXIDATION; MAJOR DEPRESSION; MENTAL DISEASE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SUBSTANTIA NIGRA; ANTAGONISTS AND INHIBITORS; BRAIN CORTEX; DRUG EFFECTS; METABOLISM; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ALDEHYDES; BIPOLAR DISORDER; CEREBRAL CORTEX; DEPRESSIVE DISORDER, MAJOR; HUMANS; HUNTINGTON DISEASE; IRON; LIPID PEROXIDATION; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSON DISEASE; SCHIZOPHRENIA; SUBSTANTIA NIGRA;

EID: 85009505654     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2016.12.046     Document Type: Review

References (218)

1. Serviddio, G., Romano, A.D., Cassano, T., Bellanti, F., Altomare, E., Vendemiale, G., Principles and therapeutic relevance for targeting mitochondria in aging and neurodegenerative diseases. Curr. Pharm. Des. 17:20 (2011), 2036–2055.
2. Kasahara, A., Scorrano, L., Mitochondria: from cell death executioners to regulators of cell differentiation. Trends Cell. Biol. 24:12 (2014), 761–770.
3. Cassano, T., Pace, L., Bedse, G., Lavecchia, A.M., De Marco, F., Gaetani, S., Serviddio, G., Glutamate and Miochondria: Two Prominent Players in the Oxidative Stress‐Induced Neurodegeneration. Curr. Alzheimer Res. 13:2 (2016), 185–197.
4. Uttara, B., Singh, A., Zamboni, P., Mahajan, R., Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 7:1 (2009), 65–74.
5. Ben-Shachar, D., Laifenfeld, D., Mitochondria, synaptic plasticity, and schizophrenia. Int. Rev. Neurobiol. 59 (2004), 273–296.
6. Dauer, W., Przedborski, S., Parkinson's disease: mechanisms and models. Neuron 39:6 (2003), 889–909.
7. Yao, J.K., Keshavan, M.S., Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid. Redox Signal. 15:7 (2011), 2011–2035.
8. Clay, H.B., Sillivan, S., Konradi, C., Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia. Int. J. Dev. Neurosci. 29:3 (2011), 311–324.
9. Manji, H., Kato, T., Di Prospero, N.A., Ness, S., Beal, M.F., Krams, M., Chen, G., Impaired mitochondrial function in psychiatric disorders. Nat. Rev. Neurosci. 13:5 (2012), 293–307.
10. Cassano, T., Serviddio, G., Gaetani, S., Romano, A., Dipasquale, P., Cianci, S., Bellanti, F., Laconca, L., Romano, A.D., Padalino, I., LaFerla, F.M., Nicoletti, F., Cuomo, V., Vendemiale, G., Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease. Neurobiol. Aging 33:6 (2012), e1–12.
11. Scola, G., Kim, H.K., Young, L.T., Andreazza, A.C., A fresh look at complex I in microarray data: clues to understanding disease- specific mitochondrial alterations in bipolar disorder. Biol. Psychiatry 73:2 (2013), e4–e5.
12. Davies, K.J., Oxidative stress: the paradox of aerobic life. Biochem. Soc. Symp. 61 (1995), 1–31.
13. Miwa, S., Brand, M.D., Mitochondrial matrix reactive oxygen species production is very sensitive to mild uncoupling. Biochem. Soc. Trans. 31:Pt 6 (2003), 1300–1301.
14. Genova, M.L., Pich, M.M., Biondi, A., Bernacchia, A., Falasca, A., Bovina, C., Formiggini, G., Parenti Castelli, G., Lenaz, G., Mitochondrial production of oxygen radical species and the role of Coenzyme Q as an antioxidant. Exp. Biol. Med. 228:5 (2003), 506–513.
15. Beckhauser, T.F., Francis-Oliveira, J., De Pasquale, R., Reactive Oxygen Species: Physiological and Physiopathological Effects on Synaptic Plasticity. J. Exp. Neurosci. 10:Suppl 1 (2016), 23–48.
16. Forman, H.J., Reactive oxygen species and alpha,beta-unsaturated aldehydes as second messengers in signal transduction. Ann. N. Y. Acad. Sci. 1203 (2010), 35–44.
17. Ayala, A., Muñoz, M.F., Argüelles, S., Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell. Longev. 8 (2014), 360–438.
18. Nordberg, J., Arnér, E.S., Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 31:11 (2001), 1287–1312.
19. Sun, Y., Oberley, L.W., Redox regulation of transcriptional activators. Free Radic. Biol. Med. 21:3 (1996), 335–348.
20. Kohen, R., Nyska, A., Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol. Pathol. 30:6 (2002), 620–650.
21. Berg, D., Youdim, M.B., Riederer, P., Redox imbalance. Cell Tissue Res. 318:1 (2004), 201–213.
22. Dix, T.A., Aikens, J., Mechanisms and biological relevance of lipid peroxidation initiation. Chem. Res. Toxicol. 6:1 (1993), 2–18.
23. Poli, G., Schaur, R.J., Siems, W.G., Leonarduzzi, G., 4-hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Med. Res. Rev. 28:4 (2008), 569–631.
24. Esterbauer, H., Schaur, R.J., Zollner, H., Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11:1 (1991), 81–128.
25. Jinsmaa, Y., Florang, V.R., Rees, J.N., Anderson, D.G., Strack, S., Doorn, J.A., Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chem. Res. Toxicol. 22:5 (2009), 835–841.
26. Dalleau, S., Baradat, M., Guéraud, F., Huc, L., Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance. Cell Death Differ. 20:12 (2013), 1615–1630.
27. Comporti, M., Lipid peroxidation and biogenic aldehydes: from the identification of 4-hydroxynonenal to further achievements in biopathology. Free Radic. Res. 28:6 (1998), 623–635.
28. Onorato, J.M., Thorpe, S.R., Baynes, J.W., Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann. N. Y. Acad. Sci. 854 (1998), 277–290.
29. Coyle, J.T., Puttfarcken, P., Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:5134 (1993), 689–695.
30. Perluigi, M., Coccia, R., Butterfield, D.A., 4-Hydroxy-2-nonenal, a reactive product of lipid peroxidation, and neurodegenerative diseases: a toxic combination illuminated by redox proteomics studies. Antioxid. Redox Signal. 17:11 (2012), 1590–1609.
31. Sultana, R., Perluigi, M., Allan Butterfield, D., Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic. Biol. Med. 62 (2013), 157–169.
32. Schaur, R.J., Basic aspects of the biochemical reactivity of 4-hydroxynonenal. Mol. Asp. Med. 24:4–5 (2003), 149–159.
33. Wataya, T., Nunomura, A., Smith, M.A., Siedlak, S.L., Harris, P.L., Shimohama, S., Szweda, L.I., Kaminski, M.A., Avila, J., Price, D.L., Cleveland, D.W., Sayre, L.M., Perry, G., High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J. Biol. Chem. 277:7 (2002), 4644–4648.
34. Barrera, G., Pizzimenti, S., Ciamporcero, E.S., Daga, M., Ullio, C., Arcaro, A., Cetrangolo, G.P., Ferretti, C., Dianzani, C., Lepore, A., Gentile, F., Role of 4-hydroxynonenal-protein adducts in human diseases. Antioxid. Redox Signal. 22:18 (2015), 1681–1702.
35. Rojo, A.I., McBean, G., Cindric, M., Egea, J., López, M.G., Rada, P., Zarkovic, N., Cuadrado, A., Redox control of microglial function: molecular mechanisms and functional significance. Antioxid. Redox Signal. 21:12 (2014), 1766–1801.
36. Mander, P., Brown, G.C., Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration. J. Neuroinflamm., 2, 2005, 20.
37. Perry, V.H., Nicoll, J.A., Holmes, C., Microglia in neurodegenerative disease. Nat. Rev. Neurol. 6:4 (2010), 193–201.
38. Di Domenico, F., Tramutola, A., Butterfield, D.A., Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders. Free Radic. Biol. Med., 2016 (pii: S0891-5849(16)(30980-7).
39. Mark, R.J., Lovell, M.A., Markesbery, W.R., Uchida, K., Mattson, M.P., A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J. Neurochem. 68:1 (1997), 255–264.
40. Mark, R.J., Pang, Z., Geddes, J.W., Uchida, K., Mattson, M.P., Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J. Neurosci. 17:3 (1997), 1046–1054.
41. Sumi, N., Nishioku, T., Takata, F., Matsumoto, J., Watanabe, T., Shuto, H., Yamauchi, A., Dohgu, S., Kataoka, Y., Lipopolysaccharide-activated microglia induce dysfunction of the blood-brain barrier in rat microvascular endothelial cells co-cultured with microglia. Cell. Mol. Neurobiol. 30:2 (2010), 247–253.
42. Ryu, K.Y., Cho, G.S., Piao, H.Z., Kim, W.K., Role of TGF-β in Survival of Phagocytizing Microglia: Autocrine Suppression of TNF‐α Production and Oxidative Stress. Exp. Neurobiol. 21:4 (2012), 151–157.
43. da Fonseca, A.C., Matias, D., Garcia, C., Amaral, R., Geraldo, L.H., Freitas, C., Lima, F.R., The impact of microglial activation on blood-brain barrier in brain diseases. Front. Cell. Neurosci., 8, 2014, 362.
44. Mertsch, K., Blasig, I., Grune, T., 4-Hydroxynonenal impairs the permeability of an in vitro rat blood-brain barrier. Neurosci. Lett. 314:3 (2001), 135–138.
45. Usatyuk, P.V., Parinandi, N.L., Natarajan, V., Redox regulation of 4-hydroxy-2-nonenal-mediated endothelial barrier dysfunction by focal adhesion, adherens, and tight junction proteins. J. Biol. Chem. 281:46 (2006), 35554–35566.
46. Riahi, Y., Cohen, G., Shamni, O., Sasson, S., Signaling and cytotoxic functions of 4-hydroxyalkenals. Am. J. Physiol. Endocrinol. Metab. 299:6 (2010), E879–E886.
47. Cohen, G., Riahi, Y., Sunda, V., Deplano, S., Chatgilialoglu, C., Ferreri, C., Kaiser, N., Sasson, S., Signaling properties of 4-hydroxyalkenals formed by lipid peroxidation in diabetes. Free Radic. Biol. Med. 65 (2013), 978–987.
48. Higdon, A., Diers, A.R., Oh, J.Y., Landar, A., Darley-Usmar, V.M., Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem. J. 442:3 (2012), 453–464.
49. Schaur, R.J., Siems, W., Bresgen, N., Eckl, P.M., 4-Hydroxy-nonenal-A Bioactive Lipid Peroxidation Product. Biomolecules 5:4 (2015), 2247–2337.
50. Zarkovic, N., Cipak, A., Jaganjac, M., Borovic, S., Zarkovic, K., Pathophysiological relevance of aldehydic protein modifications. J. Proteom. 92 (2013), 239–247.
51. Mao, L., Franke, J., Hormesis in aging and neurodegeneration-a prodigy awaiting dissection. Int. J. Mol. Sci. 14:7 (2013), 13109–13128.
52. Leonarduzzi, G., Robbesyn, F., Poli, G., Signaling kinases modulated by 4-hydroxynonenal. Free Radic. Biol. Med. 37:11 (2004), 1694–1702.
53. Ristow, M., Zarse, K., How increased oxidative stress promotes longevity and metabolic health: the concept of mitochondrial hormesis (mitohormesis). Exp. Gerontol. 45:6 (2010), 410–418.
54. Feinendegen, L.E., Bond, V.P., Sondhaus, C.A., Altman, K.I., Cellular signal adaptation with damage control at low doses versus the predominance of DNA damage at high doses. C. R. Acad. Sci. III 322:2–3 (1999), 245–251.
55. Jones, S.A., McArdle, F., Jack, C.I., Jackson, M.J., Effect of antioxidant supplementation on the adaptive response of human skin fibroblasts to UV-induced oxidative stress. Redox Rep. 4:6 (1999), 291–299.
56. Farooqui, A.A., Horrocks, L.A., Farooqui, T., Deacylation and reacylation of neural membrane glycerophospholipids. J. Mol. Neurosci. 14:3 (2000), 123–135.
57. Leonarduzzi, G., Robbesyn, F., Poli, G., Signaling kinases modulated by 4-hydroxynonenal. Free Radic. Biol. Med. 37:11 (2004), 1694–1702.
58. Ishii, T., Itoh, K., Ruiz, E., Leake, D.S., Unoki, H., Yamamoto, M., Mann, G.E., Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ. Res. 94:5 (2004), 609–616.
59. Zhang, H., Dickinson, D.A., Liu, R.M., Forman, H.J., 4-Hydroxynonenal increases gamma-glutamyl transpeptidase gene expression through mitogen-activated protein kinase pathways. Free Radic. Biol. Med. 38:4 (2005), 463–471.
60. Zhang, H., Liu, H., Iles, K.E., Liu, R.M., Postlethwait, E.M., Laperche, Y., Forman, H.J., 4-Hydroxynonenal induces rat gamma-glutamyl transpeptidase through mitogen-activated protein kinase-mediated electrophile response element/nuclear factor erythroid 2-related factor 2 signaling. Am. J. Respir. Cell. Mol. Biol. 34:2 (2006), 174–181.
61. Dickinson, D.A., Iles, K.E., Watanabe, N., Iwamoto, T., Zhang, H., Krzywanski, D.M., Forman, H.J., 4-hydroxynonenal induces glutamate cysteine ligase through JNK in HBE1 cells. Free Radic. Biol. Med., 33(7), 2002, 974.
62. Iles, K.E., Dickinson, D.A., Wigley, A.F., Welty, N.E., Blank, V., Forman, H.J., HNE increases HO-1 through activation of the ERK pathway in pulmonary epithelial cells. Free Radic. Biol. Med. 39:3 (2005), 355–364.
63. Chen, Z.H., Saito, Y., Yoshida, Y., Sekine, A., Noguchi, N., Niki, E., 4-Hydroxynonenal induces adaptive response and enhances PC12 cell tolerance primarily through induction of thioredoxin reductase 1 via activation of Nrf2. J. Biol. Chem. 280:51 (2005), 41921–41927.
64. Chen, Z.H., Yoshida, Y., Saito, Y., Noguchi, N., Niki, E., Adaptive response induced by lipid peroxidation products in cell cultures. FEBS Lett. 580:2 (2006), 479–483.
65. Halliwell, B., Gutteridge, J.M., Free Radicals in Biology and Medicine, third edition, 1999, Oxford University Press, Midsomer Norton, Avon, England.
66. Godic, A., Poljšak, B., Adamic, M., Dahmane, R., The role of antioxidants in skin cancer prevention and treatment. Oxid. Med. Cell. Longev., 2014, 2014, 860479.
67. Bouayed, J., Bohn, T., Exogenous antioxidants–Double-edged swords in cellular redox state: health beneficial effects at physiologic doses versus deleterious effects at high doses. Oxid. Med. Cell. Longev. 3:4 (2010), 228–237.
68. Zhou, Y., Zheng, J., Li, Y., Xu, D.P., Li, S., Chen, Y.M., Li, H.B., Natural Polyphenols for Prevention and Treatment of Cancer. Nutrients, 8(8), 2016, E515.
69. Poljsak, B., Šuput, D., Milisav, I., Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants. Oxid. Med. Cell. Longev., 2013, 2013, 956792.
70. Willett, W.C., The Mediterranean diet: science and practice. Public Health Nutr. 9:1A (2006), 105–110.
71. Huang, D., Ou, B., Prior, R.L., The chemistry behind antioxidant capacity assays. J. Agric. Food Chem. 53:6 (2005), 1841–1856.
72. Meganathan, P., Fu, J.Y., Biological Properties of Tocotrienols: Evidence in Human Studies. Int. J. Mol. Sci., 17(11), 2016, E1682.
73. Figueroa-Méndez, R., Rivas-Arancibia, S., Vitamin C in Health and Disease: Its Role in the Metabolism of Cells and Redox State in the Brain. Front. Physiol., 6, 2015, 397.
74. Milkovic, L., Siems, W., Siems, R., Zarkovic, N., Oxidative stress and antioxidants in carcinogenesis and integrative therapy of cancer. Curr. Pharm. Des. 20:42 (2014), 6529–6542.
75. Heo, H.J., Kim, D.O., Choi, S.J., Shin, D.H., Lee, C.Y., Apple Phenolics Protect in Vitro Oxidative Stress‐induced Neuronal Cell Death. J. Food Sci. 69 (2004), S357–S360.
76. Heo, H.J., Lee, C.Y., Strawberry and its anthocyanins reduce oxidative stress-induced apoptosis in PC12 cells. J. Agric. Food Chem. 53:6 (2005), 1984–1989.
77. Heo, H.J., Choi, S.J., Choi, S.G., Shin, D.H., Lee, J.M., Lee, C.Y., Effects of banana, orange, and apple on oxidative stress-induced neurotoxicity in PC12 cells. J. Food Sci. 73:2 (2008), H28–H32.
78. Romier, B., Van De Walle, J., During, A., Larondelle, Y., Schneider, Y.J., Modulation of signalling nuclear factor-kappaB activation pathway by polyphenols in human intestinal Caco-2 cells. Br. J. Nutr. 100:3 (2008), 542–551.
79. Romier-Crouzet, B., Van De Walle, J., During, A., Joly, A., Rousseau, C., Henry, O., Larondelle, Y., Schneider, Y.J., Inhibition of inflammatory mediators by polyphenolic plant extracts in human intestinal Caco-2 cells. Food Chem. Toxicol. 47:6 (2009), 1221–1230.
80. Luczaj, W., Siemieniuk, E., Roszkowska-Jakimiec, W., Skrzydlewska, E., Protective effect of black tea against ethanol-induced oxidative modifications of liver proteins and lipids. J. Stud. Alcohol. 67:4 (2006), 510–518.
81. Ambrożewicz, E., Augustyniak, A., Gęgotek, A., Bielawska, K., Skrzydlewska, E., Black-currant protection against oxidative stress formation. J. Toxicol. Environ. Health A 76:23 (2013), 1293–1306.
82. Hytti, M., Piippo, N., Salminen, A., Honkakoski, P., Kaarniranta, K., Kauppinen, A., Quercetin alleviates 4-hydroxynonenal-induced cytotoxicity and inflammation in ARPE-19 cells. Exp. Eye Res. 132 (2015), 208–215.
83. Wätjen, W., Michels, G., Steffan, B., Niering, P., Chovolou, Y., Kampkötter, A., Tran-Thi, Q.H., Proksch, P., Kahl, R., Low concentrations of flavonoids are protective in rat H4IIE cells whereas high concentrations cause DNA damage and apoptosis. J. Nutr. 135:3 (2005), 525–531.
84. De Marchi, U., Biasutto, L., Garbisa, S., Toninello, A., Zoratti, M., Quercetin can act either as an inhibitor or an inducer of the mitochondrial permeability transition pore: A demonstration of the ambivalent redox character of polyphenols. Biochim. Biophys. Acta 1787:12 (2009), 1425–1432.
85. Robaszkiewicz, A., Balcerczyk, A., Bartosz, G., Antioxidative and prooxidative effects of quercetin on A549 cells. Cell. Biol. Int. 31:10 (2007), 1245–1250.
86. Galati, G., O'Brien, P.J., Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties. Free Radic. Biol. Med. 37:3 (2004), 287–303.
87. Galati, G., Lin, A., Sultan, A.M., O'Brien, P.J., Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins. Free Radic. Biol. Med. 40:4 (2006), 570–580.
88. Sergediene, E., Jönsson, K., Szymusiak, H., Tyrakowska, B., Rietjens, I.M., Cenas, N., Prooxidant toxicity of polyphenolic antioxidants to HL-60 cells: description of quantitative structure-activity relationships. FEBS Lett. 462:3 (1999), 392–396.
89. Adibhatla, R.M., Hatcher, J.F., Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 12:1 (2010), 125–169.
90. Belmaker, R.H., Medical progress: bipolar disorder. N. Engl. J. Med. 351 (2004), 476–486.
91. Data-Franco, J., Singh, A., Popovic, D., Ashton, M., Berk, M., Vieta, E., Figueira, M.L., Dean, O.M., Beyond the therapeutic shackles of the monoamines: New mechanisms in bipolar disorder biology. Prog. Neuropsychopharmacol. Biol. Psychiatry 72 (2017), 73–86.
92. Shao, L., Young, L.T., Wang, J.F., Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol. Psychiatry, 58(11), 2005, 879.
93. Andreazza, A.C., Young, L.T., The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. Int. J. Neuropsychopharmacol. 17:7 (2014), 1039–1052.
94. Konradi, C., Sillivan, S.E., Clay, H.B., Mitochondria, oligodendrocytes and inflammation in bipolar disorder: evidence from transcriptome studies points to intriguing parallels with multiple sclerosis. Neurobiol. Dis. 45:1 (2012), 37–47.
95. Andreazza, A.C., Cassini, C., Rosa, A.R., Leite, M.C., de Almeida, L.M., Nardin, P., Cunha, A.B., Ceresér, K.M., Santin, A., Gottfried, C., Salvador, M., Kapczinsk, F., Gonçalves, C.A., Serum S100B and antioxidant enzymes in bipolar patients. J. Psychiatr. Res. 41:6 (2007), 523–529.
96. Wang, J.F., Shao, L., Sun, X., Young, L.T., Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord. 11:5 (2009), 523–529.
97. Allman, J.M., Hakeem, A., Erwin, J.M., Nimchinsky, E., Hof, P., The anterior cingulated cortex. The evolution of an interface between emotion and cognition. Ann. N. Y. Acad. Sci. 935 (2001), 107–117.
98. Andreazza, A.C., Gildengers, A., Rajji, T.K., Zuzarte, P.M., Mulsant, B.H., Young, L.T., Oxidative stress in older patients with bipolar disorder. Am. J. Geriatr. Psychiatry 23:3 (2015), 314–319.
99. Brown, N.C., Andreazza, A.C., Young, L.T., An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 218:1–2 (2014), 61–68.
100. Scola, G., McNamara, R.K., Croarkin, P.E., Leffler, J.M., Cullen, K.R., Geske, J.R., Biernacka, J.M., Frye, M.A., DelBello, M.P., Andreazza, A.C., Lipid peroxidation biomarkers in adolescents with or at high-risk for bipolar disorder. J. Affect. Disord. 192 (2016), 176–183.
101. Versace, A., Andreazza, A.C., Young, L.T., Fournier, J.C., Almeida, J.R., Stiffler, R.S., Lockovich, J.C., Aslam, H.A., Pollock, M.H., Park, H., Nimgaonkar, V.L., Kupfer, D.J., Phillips, M.L., Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: toward peripheral biomarkers of bipolar disorder. Mol. Psychiatry 19:2 (2014), 200–208.
102. Tan, H., Young, L.T., Shao, L., Che, Y., Honer, W.G., Wang, J.F., Mood stabilizer lithium inhibits amphetamine-increased 4-hydroxynonenal-protein adducts in rat frontal cortex. Int. J. Neuropsychopharmacol. 15:9 (2012), 1275–1285.
103. Wiste, A.K., Arango, V., Ellis, S.P., Mann, J.J., Underwood, M.D., Norepinephrine and serotonin imbalance in the locus coeruleus in bipolar disorder. Bipolar Disord. 10:3 (2008), 349–359.
104. Cousins, D.A., Butts, K., Young, A.H., The role of dopamine in bipolar disorder. Bipolar Disord. 11:8 (2009), 787–806.
105. Trent, S., Cassano, T., Bedse, G., Ojarikre, O.A., Humby, T., Davies, W., Altered serotonergic function may partially account for behavioral endophenotypes in steroid sulfatase-deficient mice. Neuropsychopharmacology 37:5 (2012), 1267–1274.
106. Trent, S., Dean, R., Veit, B., Cassano, T., Bedse, G., Ojarikre, O.A., Humby, T., Davies, W., Biological mechanisms associated with increased perseveration and hyperactivity in a genetic mouse model of neurodevelopmental disorder. Psychoneuroendocrinology 38:8 (2013), 1370–1380.
107. Bymaster, F.P., Felder, C.C., Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Mol. Psychiatry 1 (2002), S57–S63.
108. Muglia, P., Petronis, A., Mundo, E., Lander, S., Cate, T., Kennedy, J.L., Dopamine D4 receptor and tyrosine hydroxylase genes in bipolar disorder: evidence for a role of DRD4. Mol. Psychiatry 7:8 (2002), 860–866.
109. Kugaya, A., Sanacora, G., Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr. 10:10 (2005), 808–819.
110. Blanc, E.M., Kelly, J.F., Mark, R.J., Waeg, G., Mattson, M.P., 4-Hydroxynonenal, an aldehydic product of lipid peroxidation, impairs signal transduction associated with muscarinic acetylcholine and metabotropic glutamate receptors: possible action on G alpha (q/11). J. Neurochem. 69:2 (1997), 570–580.
111. Harro, J., Oreland, L., Depression as a spreading adjustment disorder of monoaminergic neurons: a case for primary implication of the locus coeruleus. Brain Res. 38:1–2 (2001), 79–128.
112. Cassano, T., Gaetani, S., Morgese, M.G., Macheda, T., Laconca, L., Dipasquale, P., Taltavull, J., Shippenberg, T.S., Cuomo, V., Gobbi, G., Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion. Neurochem. Res. 34:8 (2009), 1417–1426.
113. Gardner, A., Boles, R.G., Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 35:3 (2011), 730–743.
114. Tobe, E.H., Mitochondrial dysfunction, oxidative stress, and major depressive disorder. Neuropsychiatr. Dis. Treat. 9 (2013), 567–573.
115. Gardner, A., Johansson, A., Wibom, R., Nennesmo, I., von Döbeln, U., Hagenfeldt, L., Hällström, T., Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J. Affect. Disord. 76:1–3 (2003), 55–68.
116. Rezin, G.T., Amboni, G., Zugno, A.I., Quevedo, J., Streck, E.L., Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res. 34:6 (2009), 1021–1029.
117. Selley, M.L., Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J. Affect. Disord. 80:2–3 (2004), 249–256.
118. Maes, M., Major depression and activation of the inflammatory response system. Adv. Exp. Med. Biol. 461 (1999), 25–46.
119. Maes, M., De Vos, N., Pioli, R., Demedts, P., Wauters, A., Neels, H., Christophe, A., Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J. Affect. Disord. 58:3 (2000), 241–246.
120. Bilici, M., Efe, H., Köroğlu, M.A., Uydu, H.A., Bekaroğlu, M., Değer, O., Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J. Affect. Disord. 64:1 (2001), 43–51.
121. Demas, G.E., Kriegsfeld, L.J., Blackshaw, S., Huang, P., Gammie, S.C., Nelson, R.J., Snyder, S.H., Elimination of aggressive behaviour in male mice lacking endothelial nitric oxide synthase. J. Neurosci., 19(19), 1999, RC30.
122. Snyder, S.H., Ferris, C.D., Novel neurotransmitters and their neuropsychiatric relevance. Am. J. Psychiatry 157:11 (2000), 1738–1751.
123. Frisch, C., Dere, E., Silva, M.A., Godecke, A., Schrader, J., Huston, J.P., Superior water maze performance and increase in fear-related behavior in the endothelial nitric oxide synthase-deficient mouse together with monoamine changes in cerebellum and ventral striatum. J. Neurosci. 20:17 (2000), 6694–6700.
124. Graeff, F.G., Guimarães, F.S., De Andrade, T.G., Deakin, J.F., Role of 5-HT in stress, anxiety, and depression. Pharmacol. Biochem. Behav. 54:1 (1996), 129–141.
125. Stachowicz, A., Głombik, K., Olszanecki, R., Basta-Kaim, A., Suski, M., Lasoń, W., Korbut, R., The impact of mitochondrial aldehyde dehydrogenase (ALDH2) activation by Alda-1 on the behavioral and biochemical disturbances in animal model of depression. Brain Behav. Immun. 51 (2016), 144–153.
126. Chen, C.H., Ferreira, J.C., Gross, E.R., Mochly-Rosen, D., Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiol. Rev. 94:1 (2014), 1–34.
127. Klyosov, A.A., Kinetics and specificity of human liver aldehyde dehydrogenases toward aliphatic, aromatic, and fused polycyclic aldehydes. Biochemistry 35 (1996), 4457–4467.
128. Chen, C.H., Sun, L., Mochly-Rosen, D., Mitochondrial aldehyde dehydrogenase and cardiac diseases. Cardiovasc. Res. 88:1 (2010), 51–57.
129. Yoval-Sanchez, B., Rodriguez-Zavala, J.S., Differences in susceptibility to inactivation of human aldehyde dehydrogenases by lipid peroxidation byproducts. Chem. Res. Toxicol. 25 (2012), 722–729.
130. Stewart, M.J., Malek, K., Crabb, D.W., Distribution of messenger RNAs for aldehyde dehydrogenase 1, aldehyde dehydrogenase 2, and aldehyde dehydrogenase 5 in human tissues. J. Investig. Med. 44 (1996), 42–46.
131. Oyama, T., Isse, T., Kagawa, N., Kinaga, T., Kim, Y.D., Morita, M., Sugio, K., Weiner, H., Yasumoto, K., Kawamoto, T., Tissue-distribution of aldehyde dehydrogenase 2 and effects of the ALDH2 gene-disruption on the expression of enzymes involved in alcohol metabolism. Front. Biosci. 10 (2005), 951–960.
132. Perez-Miller, S., Younus, H., Vanam, R., Chen, C.H., Mochly-Rosen, D., Hurley, T.D., Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant. Nat. Struct. Mol. Biol. 17:2 (2010), 159–164.
133. Feng, Z., Zou, X., Jia, H., Li, X., Zhu, Z., Liu, X., Bucheli, P., Ballevre, O., Hou, Y., Zhang, W., Wang, J., Chen, Y., Liu, J., Maternal docosahexaenoic acid feeding protects against impairment of learning and memory and oxidative stress in prenatally stressed rats: possible role of neuronal mitochondria metabolism. Antioxid. Redox Signal. 16:3 (2012), 275–289.
134. American Psychiatric Association, Diagnostic and statistical manual of mental disorders, 5th ed., 2013, Washington, DC.
135. Hoskins, R.G., Oxygen metabolism in schizophrenia. Arch. Neurol. Psychiatry 38:6 (1937), 1261–1270.
136. Bošković, M., Vovk, T., Kores Plesničar, B., Grabnar, I., Oxidative stress in schizophrenia. Curr. Neuropharmacol. 9:2 (2011), 301–312.
137. Emiliani, F.E., Sedlak, T.W., Sawa, A., Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr. Opin. Psychiatry 27:3 (2014), 185–190.
138. Young, J., McKinney, S.B., Ross, B.M., Wahle, K.W., Boyle, S.P., Biomarkers of oxidative stress in schizophrenic and control subjects. Prostaglandins Leukot. Essent. Fat. Acids 76:2 (2007), 73–85.
139. Uchida, K., 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 42:4 (2003), 318–343.
140. Halliwell, B., Whiteman, M., Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?. Br. J. Pharmacol. 142:2 (2004), 231–255.
141. Cordes, J.S., Mathiak, K.A., Dyck, M., Alawi, E.M., Gaber, T.J., Zepf, F.D., Klasen, M., Zvyagintsev, M., Gur, R.C., Mathiak, K., Cognitive and neural strategies during control of the anterior cingulate cortex by fMRI neurofeedback in patients with schizophrenia. Front. Behav. Neurosci., 9, 2015, 169.
142. Sanders, G.S., Gallup, G.G., Heinsen, H., Hof, P.R., Schmitz, C., Cognitive deficits, schizophrenia, and the anterior cingulate cortex. Trends Cogn. Sci. 6:5 (2002), 190–192.
143. Fornito, A., Yücel, M., Dean, B., Wood, S.J., Pantelis, C., Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. Schizophr. Bull. 35:5 (2009), 973–993.
144. Kropp, S., Kern, V., Lange, K., Degner, D., Hajak, G., Kornhuber, J., Rüther, E., Emrich, H.M., Schneider, U., Bleich, S., Oxidative stress during treatment with first- and second-generation antipsychotics. J. Neuropsychiatry Clin. Neurosci. 17:2 (2005), 227–231.
145. Wei, Z., Bai, O., Richardson, J.S., Mousseau, D.D., Li, X.M., Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J. Neurosci. Res. 73:3 (2003), 364–368.
146. Pillai, A., Parikh, V., Terry, A.V., Jr, Mahadik, S.P., Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 41:5 (2007), 372–386.
147. Medina-Hernández, V., Ramos-Loyo, J., Luquin, S., Sánchez, L.F., García-Estrada, J., Navarro-Ruiz, A., Increased lipid peroxidation and neuron specific enolase in treatment refractory schizophrenics. J. Psychiatr. Res. 41:8 (2007), 652–658.
148. Harding, C.M., Zubin, J., Strauss, J.S., Chronicity in schizophrenia: revisited. Br. J. Psychiatry Suppl. 18 (1992), 27–37.
149. Brenner, H., Merlo, M., Definition of therapy-resistant schizophrenia and its assessment. Eur. Psychiatry 10:Suppl. 1 (1995), S11–S17.
150. Joober, R., Rouleau, G.A., Lal, S., Dixon, M., O'Driscoll, G., Palmour, R., Annable, L., Bloom, D., Lalonde, P., Labelle, A., Benkelfat, C., Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers. Schizophr. Res. 53:3 (2002), 229–238.
151. Ramos, J., Cerdán, L.F., Guevara, M.A., Amezcua, C., Impairments in attention and facial emotion recognition in treatment of refractory and non refractory schizophrenics evaluated through an odd-ball paradigm. Rev. Neurol. 33:11 (2001), 1027–1032.
152. Halbreich, U., Kahn, L.S., Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology 28:Suppl. 2 (2003), S1–S16.
153. Ramos-Loyo, J., Medina-Hernández, V., Estarrón-Espinosa, M., Canales-Aguirre, A., Gómez-Pinedo, U., Cerdán-Sánchez, L.F., Sex differences in lipid peroxidation and fatty acid levels in recent onset schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 44 (2013), 154–161.
154. Rao, M.L., Kölsch, H., Effects of estrogen on brain development and neuroprotection–implications for negative symptoms in schizophrenia. Psychoneuroendocrinology 28:Suppl. 2 (2003), S83–S96.
155. Robinson, J.G., Ijioma, N., Harris, W., Omega-3 fatty acids and cognitive function in women. Women's Health 6:1 (2010), 119–134.
156. Pla, P., Orvoen, S., Saudou, F., David, D.J., Humbert, S., Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms. Front. Behav. Neurosci., 8, 2014, 135.
157. Zuccato, C., Cattaneo, E., Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5:6 (2009), 311–322.
158. Kim, S., Kim, K.T., Therapeutic Approaches for Inhibition of Protein Aggregation in Huntington's Disease. Exp. Neurobiol. 23:1 (2014), 36–44.
159. Bates, G.P., Dorsey, R., Gusella, J.F., Hayden, M.R., Kay, C., Leavitt, B.R., Nance, M., Ross, C.A., Scahill, R.I., Wetzel, R., Wild, E.J., Tabrizi, S.J., Huntington disease. Nat. Rev. Dis. Prim., 1, 2015, 15005.
160. Johri, A., Chandra, A., Beal, M.F., PGC-1α, mitochondrial dysfunction, and Huntington's disease. Free Radic. Biol. Med. 62 (2013), 37–46.
161. Lee, J., Kosaras, B., Del Signore, S.J., Cormier, K., McKee, A., Ratan, R.R., Kowall, N.W., Ryu, H., Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice. Acta Neuropathol. 121:4 (2011), 487–498.
162. Chiu, E., Alexander, L., Causes of death in Huntington's disease. Med. J. Aust., 1(4), 1982, 153.
163. Lanska, D.J., Lavine, L., Lanska, M.J., Schoenberg, B.S., Huntington's disease mortality in the United States. Neurology 38:5 (1988), 769–772.
164. Sorensen, S.A., Fenger, K., Causes of death in patients with Huntington's disease and in unaffected first degree relatives. J. Med. Genet. 29:12 (1992), 911–914.
165. Lin, C.L., Wang, S.E., Hsu, C.H., Sheu, S.J., Wu, C.H., Oral treatment with herbal formula B307 alleviates cardiac failure in aging R6/2 mice with Huntington's disease via suppressing oxidative stress, inflammation, and apoptosis. Clin. Interv. Aging 10 (2015), 1173–1187.
166. Wu, Z., Puigserver, P., Andersson, U., Zhang, C., Adelmant, G., Mootha, V., Troy, A., Cinti, S., Lowell, B., Scarpulla, R.C., Spiegelman, B.M., Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98:1 (1999), 115–124.
167. Tsunemi, T., Ashe, T.D., Morrison, B.E., Soriano, K.R., Au, J., Roque, R.A., Lazarowski, E.R., Damian, V.A., Masliah, E., La Spada, A.R., PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Sci. Transl. Med 4:142 (2012), 142–197.
168. Fahn, S., Description of Parkinson's disease as a clinical syndrome. Ann. N. Y. Acad. Sci. 991 (2003), 1–14.
169. Branchi, I., D'Andrea, I., Armida, M., Cassano, T., Pèzzola, A., Potenza, R.L., Morgese, M.G., Popoli, P., Alleva, E., Nonmotor symptoms in Parkinson's disease: investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model. J. Neurosci. Res. 86:9 (2008), 2050–2061.
170. Branchi, I., D'Andrea, I., Armida, M., Carnevale, D., Ajmone-Cat, M.A., Pèzzola, A., Potenza, R.L., Morgese, M.G., Cassano, T., Minghetti, L., Popoli, P., Alleva, E., Striatal 6-OHDA lesion in mice: investigating early neurochemical changes underlying Parkinson's disease. Behav. Brain Res. 208:1 (2010), 137–143.
171. Aureli, C., Cassano, T., Masci, A., Francioso, A., Martire, S., Cocciolo, A., Chichiarelli, S., Romano, A., Gaetani, S., Mancini, P., Fontana, M., d'Erme, M., Mosca, L., 5-S-cysteinyldopamine neurotoxicity: influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease. J. Neurosci. Res. 92:3 (2014), 347–358.
172. Javed, H., Kamal, M.A., Ojha, S., An overview on the role of α-synuclein inexperimental models of Parkinson's disease from pathogenesis to therapeutics. CNS Neurol. Disord. Drug Targets, 2016.
173. Youdim, M.B., Ben-Shachar, D., Riederer, P., Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?. Acta Neurol. Scand. Suppl. 126 (1989), 47–54.
174. Jenner, P., Oxidative stress as a cause of Parkinson's disease. Acta Neurol. Scand. Suppl. 136 (1991), 6–15.
175. Jenner, P., Schapira, A.H., Marsden, C.D., New insights into the cause of Parkinson's disease. Neurology 42:12 (1992), 2241–2250.
176. Halliwell, B., Reactive oxygen species and the central nervous system. J. Neurochem. 59:5 (1992), 1609–1623.
177. Jenner, P., Oxidative damage in neurodegenerative disease. Lancet 344:8925 (1994), 796–798.
178. Olanow, C.W., Tatton, W.G., Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22 (1999), 123–144.
179. Oueslati, A., Fournier, M., Lashuel, H.A., Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res. 183 (2010), 115–145.
180. Jaisson, S., Gillery, P., Evaluation of nonenzymatic posttranslational modification-derived products as biomarkers of molecular aging of proteins. Clin. Chem. 56:9 (2010), 1401–1412.
181. Qin, Z., Hu, D., Han, S., Reaney, S.H., Di Monte, D.A., Fink, A.L., Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J. Biol. Chem. 282:8 (2007), 5862–5870.
182. Hattoria, N., Wanga, M., Taka, H., Fujimura, T., Yoritaka, A., Kubo, S., Mochizuki, H., Toxic effects of dopamine metabolism in Parkinson's disease. Park. Relat. Disord. 15:Suppl. 1 (2009), S35–S38.
183. Xiang, W., Schlachetzki, J.C., Helling, S., Bussmann, J.C., Berlinghof, M., Schäffer, T.E., Marcus, K., Winkler, J., Klucken, J., Becker, C.M., Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity. Mol. Cell Neurosci. 54 (2013), 71–83.
184. Näsström, T., Fagerqvist, T., Barbu, M., Karlsson, M., Nikolajeff, F., Kasrayan, A., Ekberg, M., Lannfelt, L., Ingelsson, M., Bergström, J., The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of α-synuclein oligomers with distinct biochemical, morphological, and functional properties. Free Radic. Biol. Med. 50:3 (2011), 428–437.
185. Scholz, D., Pöltl, D., Genewsky, A., Weng, M., Waldmann, T., Schildknecht, S., Leist, M., Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J. Neurochem. 119:5 (2011), 957–971.
186. McNaught, K.S., Olanow, C.W., Halliwell, B., Isacson, O., Jenner, P., Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2:8 (2001), 589–594.
187. Okada, K., Wangpoengtrakul, C., Osawa, T., Toyokuni, S., Tanaka, K., Uchida, K., 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J. Biol. Chem. 274:34 (1999), 23787–23793.
188. + ATPase in rat striatal synaptosomes. Neurochem. Int. 33:6 (1998), 531–540.
189. Shin, Y., White, B.H., Uh, M., Sidhu, A., Modulation of D1-like dopamine receptor function by aldehydic products of lipid peroxidation. Brain Res. 968:1 (2003), 102–113.
190. Castellani, R.J., Perry, G., Siedlak, S.L., Nunomura, A., Shimohama, S., Zhang, J., Montine, T., Sayre, L.M., Smith, M.A., Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci. Lett. 319:1 (2002), 25–28.
191. Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E.R., Mizuno, Y., Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA 93:7 (1996), 2696–2701.
192. Hao, R., Norgren, R.B. Jr, Lau, Y.S., Pfeiffer, R.F., Cerebrospinal fluid of Parkinson's disease patients inhibits the growth and function of dopaminergic neurons in culture. Neurology 45:1 (1995), 138–142.
193. Selley, M.L., (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic. Biol. Med. 25:2 (1998), 169–174.
194. Calne, D., Schulzer, M., Mak, E., Stoessl, A.J., Treatment for the progression of Parkinson's disease. Lancet Neurol., 4(4), 2005, 206.
195. Trapani, A., De Giglio, E., Cafagna, D., Denora, N., Agrimi, G., Cassano, T., Gaetani, S., Cuomo, V., Trapani, G., Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int. J. Pharm. 419:1–2 (2011), 296–307.
196. Denora, N., Cassano, T., Laquintana, V., Lopalco, A., Trapani, A., Cimmino, C.S., Laconca, L., Giuffrida, A., Trapani, G., Novel codrugs with GABAergic activity for dopamine delivery in the brain. Int. J. Pharm. 437:1–2 (2012), 221–231.
197. Di Gioia, S., Trapani, A., Mandracchia, D., De Giglio, E., Cometa, S., Mangini, V., Arnesano, F., Belgiovine, G., Castellani, S., Pace, L., Lavecchia, M.A., Trapani, G., Conese, M., Puglisi, G., Cassano, T., Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-β-cyclodextrin based nanoparticles. Eur. J. Pharm. Biopharm. 94 (2015), 180–193.
198. Morgese, M.G., Cassano, T., Cuomo, V., Giuffrida, A., Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp. Neurol. 208:1 (2007), 110–119.
199. Morgese, M.G., Cassano, T., Gaetani, S., Macheda, T., Laconca, L., Dipasquale, P., Ferraro, L., Antonelli, T., Cuomo, V., Giuffrida, A., Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochem. Int. 54:1 (2009), 56–64.
200. Varanese, S., Howard, J., Di Rocco, A., NMDA antagonist memantine improves levodopa-induced dyskinesias and “on-off” phenomena in Parkinson's disease. Mov. Disord. 25:4 (2010), 508–510.
201. Martinez, A.A., Morgese, M.G., Pisanu, A., Macheda, T., Paquette, M.A., Seillier, A., Cassano, T., Carta, A.R., Giuffrida, A., Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Neurobiol. Dis. 74 (2015), 295–304.
202. Fitzmaurice, A.G., Rhodes, S.L., Lulla, A., Murphy, N.P., Lam, H.A., O'Donnell, K.C., Barnhill, L., Casida, J.E., Cockburn, M., Sagasti, A., Stahl, M.C., Maidment, N.T., Ritz, B., Bronstein, J.M., Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc. Natl. Acad. Sci. USA 110:2 (2013), 636–641.
203. Ohta, S., Ohsawa, I., Kamino, K., Ando, F., Shimokata, H., Mitochondrial ALDH2 deficiency as an oxidative stress. Ann. N. Y. Acad. Sci. 1011 (2004), 36–44.
204. Marchitti, S.A., Deitrich, R.A., Vasiliou, V., Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol. Rev. 59:2 (2007), 125–150.
205. Panneton, W.M., Kumar, V.B., Gan, Q., Burke, W.J., Galvin, J.E., The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS One, 5(12), 2010, e15251.
206. Goldstein, D.S., Sullivan, P., Holmes, C., Miller, G.W., Alter, S., Strong, R., Mash, D.C., Kopin, I.J., Sharabi, Y., Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J. Neurochem. 126:5 (2013), 591–603.
207. Wey, M.C., Fernandez, E., Martinez, P.A., Sullivan, P., Goldstein, D.S., Strong, R., Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PLoS One, 7(2), 2012, e31522.
208. Chiu, C.C., Yeh, T.H., Lai, S.C., Wu-Chou, Y.H., Chen, C.H., Mochly-Rosen, D., Huang, Y.C., Chen, Y.J., Chen, C.L., Chang, Y.M., Wang, H.L., Lu, C.S., Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism. Exp. Neurol. 263 (2015), 244–253.
209. Inden, M., Kitamura, Y., Kondo, J., Hayashi, K., Yanagida, T., Takata, K., Tsuchiya, D., Yanagisawa, D., Nishimura, K., Taniguchi, T., Shimohama, S., Sugimoto, H., Akaike, A., Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats. J. Neurochem. 95:4 (2005), 950–961.
210. Costa, L.G., Garrick, J.M., Roquè, P.J., Pellacani, C., Mechanisms of Neuroprotection by Quercetin: Counteracting Oxidative Stress and More. Oxid. Med. Cell Longev., 2016, 2016, 2986796.
211. Lv, C., Hong, T., Yang, Z., Zhang, Y., Wang, L., Dong, M., Zhao, J., Mu, J., Meng, Y., Effect of Quercetin in the 1‐Methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine‐Induced Mouse Model of Parkinson's Disease. Evid. Based Complement. Altern. Med., 2012, 2012, 928643.
212. El-Horany, H.E., El-Latif, R.N., ElBatsh, M.M., Emam, M.N., Ameliorative Effect of Quercetin on Neurochemical and Behavioral Deficits in Rotenone Rat Model of Parkinson's Disease: Modulating Autophagy (Quercetin on Experimental Parkinson's Disease). J. Biochem. Mol. Toxicol. 30:7 (2016), 360–369.
213. Fujita, K., Seike, T., Yutsudo, N., Ohno, M., Yamada, H., Yamaguchi, H., Sakumi, K., Yamakawa, Y., Kido, M.A., Takaki, A., Katafuchi, T., Tanaka, Y., Nakabeppu, Y., Noda, M., Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. PLoS One, 4(9), 2009, e7247.
214. Dexter, D.T., Wells, F.R., Agid, F., Agid, Y., Lees, A.J., Jenner, P., Marsden, C.D., Increased nigral iron content in postmortem parkinsonian brain. Lancet 2:8569 (1987), 1219–1220.
215. Devos, D., Moreau, C., Devedjian, J.C., Kluza, J., Petrault, M., Laloux, C., Jonneaux, A., Ryckewaert, G., Garçon, G., Rouaix, N., Duhamel, A., Jissendi, P., Dujardin, K., Auger, F., Ravasi, L., Hopes, L., Grolez, G., Firdaus, W., Sablonnière, B., Strubi-Vuillaume, I., Zahr, N., Destée, A., Corvol, J.C., Pöltl, D., Leist, M., Rose, C., Defebvre, L., Marchetti, P., Cabantchik, Z.I., Bordet, R., Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid. Redox Signal 21:2 (2014), 195–210.
216. Goldman, S., Environmental toxins and Parkinson's disease. Annu. Rev. Pharmacol. Toxicol. 54 (2014), 141–164.
217. Matak, P., Matak, A., Moustafa, S., Aryal, D.K., Benner, E.J., Wetsel, W., Andrews, N.C., Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice. Proc. Natl. Acad. Sci. USA 113:13 (2016), 3428–3435.
218. Connor, J.R., Menzies, S.L., St Martin, S.M., Mufson, E.J., Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J. Neurosci. Res. 27:4 (1990), 595–611.